Abstract:On-target off-tumor toxicity, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe immune-related adverse events (irAEs) that are frequently associated with Chimeric Antigen Receptor (CAR) T-cell therapy. Current efforts to manage such therapy-related toxicities involve incorporation of an inducible suicide agent within CAR constructs, such as iCaspase-9 or herpes simplex virus type 1 thymidine kinase that can be selectively activated to produce toxic effects within CAR T cells and attenuate their activity. However, while activation of these agents helps to mitigate or overcome such unwarranted toxicities, the therapeutic benefit of CAR T cells anti-tumor activity is also compromised. Therefore, to continue maintenance of CAR T cells' therapeutic function while minimizing irAEs, an ideal safety switch should 1) rapidly inhibit the activation and proliferation of CAR T cells exposed to the target antigen, 2) reversibly inhibit activity without inducing CAR T cell elimination and 3) be clinically translatable for safe application in patients. Our laboratory investigated one such safety switch to inhibit CAR T-cell activity while maintaining their therapeutic function. We showed that incorporating a mutant variant of c-KIT D816V (KITv) in the intracellular domain of mesothelin-targeting second-generation CAR T cells (M28z-KITv) improved efficacy in solid tumors with low antigen, or an immunosuppressive environment. Herein, we evaluate the use of Dasatinib, a clinically available multitarget (BCR, SRC, c-KIT) tyrosine kinase inhibitor (TKI), as a tunable safety switch to reversibly inhibit M28z-KITv CAR T-cell functional activity. In cohorts of mice established with lung adenocarcinoma, daily administration of Dasatinib starting on day 1 or day 3 after CAR T-cell administration stabilized tumor growth, which otherwise continued to regress in untreated mice, indicating inhibition of CAR T-cell functional activity. Upon discontinuation of Dasatinib, tumors regressed, indicating reversal of CAR T-cell functional activity. In an experiment conducted to investigate functional persistence of CAR T cells upon long-term exposure to Dasatinib (1 month), we noted uninhibited activity of CAR T cells to rechallenged tumors. Dasatinib, thus may act as a tunable safety switch to regulate M28z-KITv CAR T-cell activity without compromising its therapeutic function. Citation Format: Kyohei Misawa, Meriem Taleb, Srijita Banerjee, William-Ray Vista, Navin K. Chintala, Prasad S. Adusumilli. A tunable safety switch for solid tumor CAR T-cell therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3993.

Safety switches for adoptive cell therapy

Enhancing the Safety of CAR-T Cell Therapy: Synthetic Genetic Switch for Spatiotemporal Control.

Adoptive T-cell therapy: adverse events and safety switches

Small molecule-regulated switches to provide functional control of CAR T cells within the patient

Abstract 3993: A tunable safety switch for solid tumor CAR T-cell therapy

Versatile strategy for controlling the specificity and activity of engineered T cells

Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory

Switch-mediated Activation and Retargeting of CAR-T Cells for B-cell Malignancies

Engineering programmable CAR-T cells with tunable controls as fail-safe mechanisms during cancer immunotherapy

Abstract 6321: Developing a lenalidomide-inducible safety switch for CAR T cell therapy

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity

Enhancing cell‐based therapies with synthetic gene circuits responsive to molecular stimuli

Developing and characterizing a two-layered safety switch for cell therapies

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Cytokine Release Syndrome in Cancer Immunotherapy with Chimeric Antigen Receptor Engineered T Cells.

Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors (adv. Sci. 12/2023)

A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells

Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review

Photoswitchable CAR-T Cell Function In Vitro and In Vivo via a Cleavable Mediator

Generation of T cells with reduced off-target cross-reactivities by engineering co-signalling receptors